{"id":"intramuscular-glucagon","safety":{"commonSideEffects":[{"rate":"25–30","effect":"Nausea"},{"rate":"10–15","effect":"Vomiting"},{"rate":"5–10","effect":"Headache"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL5314342","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glucagon is a peptide hormone that activates glucagon receptors (GCGRs) on hepatocytes, triggering intracellular signaling cascades that promote the breakdown of stored glycogen and synthesis of new glucose. This mechanism is used acutely to reverse severe hypoglycemia by rapidly mobilizing endogenous glucose production. Intramuscular administration provides a non-intravenous route for emergency treatment when oral glucose is not feasible.","oneSentence":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:39.370Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe hypoglycemia in patients with diabetes"}]},"trialDetails":[{"nctId":"NCT03421379","phase":"PHASE3","title":"A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-02-21","conditions":"Diabetes Mellitus","enrollment":75},{"nctId":"NCT01994746","phase":"PHASE3","title":"Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11","conditions":"Diabetes Mellitus, Type 1","enrollment":77},{"nctId":"NCT03339453","phase":"PHASE1","title":"A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-11-10","conditions":"Hypoglycemia, Diabetes Mellitus, Type 1","enrollment":70},{"nctId":"NCT01959334","phase":"PHASE3","title":"Evaluate the Immunogenicity of a Novel Glucagon Formulation","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-09","conditions":"Drug-specific Antibodies, Diabetes Mellitus","enrollment":75},{"nctId":"NCT01640834","phase":"PHASE1","title":"Study of LY2409021 in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Diabetes Mellitus, Type 1","enrollment":20},{"nctId":"NCT01997411","phase":"PHASE2, PHASE3","title":"Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11","conditions":"Diabetes Mellitus, Type 1","enrollment":48},{"nctId":"NCT00745186","phase":"PHASE1","title":"Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers","status":"COMPLETED","sponsor":"Hospira, now a wholly owned subsidiary of Pfizer","startDate":"2007-08","conditions":"Hypoglycemia","enrollment":28},{"nctId":"NCT02403648","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons","status":"COMPLETED","sponsor":"Biodel","startDate":"2014-11","conditions":"Hypoglycemia","enrollment":15},{"nctId":"NCT02240043","phase":"NA","title":"Growth Hormone Evaluation in the Elderly People","status":"COMPLETED","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2011-09","conditions":"Aging","enrollment":48},{"nctId":"NCT01079715","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Propranolol in Newborns With Retinopathy of Prematurity","status":"COMPLETED","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2010-01","conditions":"Retinopathy of Prematurity","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":64,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GlucaGen HypoKit","GlucaGen®"],"phase":"phase_3","status":"active","brandName":"Intramuscular Glucagon","genericName":"Intramuscular Glucagon","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels. Used for Severe hypoglycemia in patients with diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}